Advertisement

Topics

FDA Expands Approval Of Bristol-Myers Squibb Myeloid Leukemia Treatment

07:16 EST 13 Nov 2017 | Pharmaceutical Processing

Sprycel is the first and only second-generation tyrosine kinase inhibitor approved for children with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase.
Contributed Author: 
Bristol-Myers Squibb Company

Original Article: FDA Expands Approval Of Bristol-Myers Squibb Myeloid Leukemia Treatment

NEXT ARTICLE

More From BioPortfolio on "FDA Expands Approval Of Bristol-Myers Squibb Myeloid Leukemia Treatment"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Pediatrics
Pediatrics is the general medicine of childhood. Because of the developmental processes (psychological and physical) of childhood, the involvement of parents, and the social management of conditions at home and at school, pediatrics is a specialty. With ...

Bioinformatics
Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...